Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

Core Insights - Zentalis Pharmaceuticals is presenting updated clinical data from the ongoing Phase 2 DENALI trial of azenosertib for patients with platinum-resistant ovarian cancer (PROC) at the SGO 2025 Annual Meeting [1] - Azenosertib is a potentially first-in-class WEE1 inhibitor being evaluated as a monotherapy and in combination across multiple tumor types, showing anti-tumor activity and good tolerability in clinical trials [2] Company Overview - Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing azenosertib (ZN-c3) for Cyclin E1+ platinum-resistant ovarian cancer [2] - The company is leveraging its expertise to explore additional research opportunities for azenosertib beyond PROC [2] Presentation Details - The oral presentation titled "Cyclin E1 is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer (PROC): Outcomes from Part 1b of the DENALI Study (GOG-3066)" will be presented by Dr. Fiona Simpkins on March 15 [4] - A poster presentation on the synergistic antitumor effects of azenosertib with microtubule inhibitor-based ADCs will be presented by Dr. Joanna Guo on March 16 [4]